天弘国证生物医药ETF发起式联接C(011041)财务指标
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 本期已实现收益 |
-94,742,890.45 |
-80,451,749.28 |
-31,365,768.60 |
-109,246,204.12 |
| 本期利润 |
23,769,353.09 |
-240,430,078.73 |
-297,641,257.01 |
-214,448,167.50 |
| 加权平均基金份额本期利润 |
0.01 |
-0.11 |
-0.14 |
-0.11 |
| 本期加权平均净值利润率(%) |
2.64 |
-26.67 |
-33.23 |
-20.41 |
| 本期基金份额净值增长率(%) |
1.98 |
-22.04 |
-27.05 |
-19.00 |
| 期末可供分配利润 |
-1,276,247,664.91 |
-1,431,114,570.41 |
-1,483,296,226.12 |
-1,031,376,099.32 |
| 期末可供分配基金份额利润 |
-0.60 |
-0.61 |
-0.63 |
-0.50 |
| 期末基金资产净值 |
855,247,362.51 |
928,089,688.33 |
863,966,991.97 |
1,050,499,023.93 |
| 期末基金份额净值 |
0.40 |
0.39 |
0.37 |
0.50 |
| 基金份额累计净值增长率(%) |
-59.88 |
-60.66 |
-63.19 |
-49.54 |
微信公众号
证券之星APP
基本资料
